1 In the present study, we have pharmacologically characterized two novel mixed endothelin ET A /ET B receptor antagonists, namely BQ-928 and BQ-238, in ET A and ET B preparations, the rabbit carotid artery (RbCA) and the rabbit pulmonary artery (RbPA), respectively. These two antagonists were compared to established ET A (BQ-123 and BMS 182874), ET B (BQ-788) and mixed ET A /ET B (SB 209670) receptor antagonists. 2 In the RbCA, the ET A monoreceptor preparation, BQ-238 and BQ-928 had apparent anities (pA 2 ) of 7.42+0.22 and 7.22+0.18, respectively, BQ-788 being inactive in this preparation. In the ET B monoreceptor preparation, the RbPA (when IRL-1620 was used as an ET B receptor agonist), the pA 2 for BQ-238 was 7.05+0.14 and for BQ-928 was 8.43+0.04. BQ-123 and BMS 182874 were inactive in this preparation. Similar to SB 209670, BQ-238 but not BQ-928 had a higher anity for the ET A than the ET B receptor. 3 All of the antagonists were tested for their ability to block and reverse endothelin-1-induced vasoconstrictions in the rabbit perfused kidney. In this preparation endothelin-1-induced increases in vascular resistance have been shown to be mediated solely by ET A receptors. All compounds (except BQ-788) blocked the pressor eects of endothelin within the kidney; the calculated IC 50 values for BQ-123, BMS 182874, SB 209670, BQ-928 and BQ-238 were 0.4 mM, 2 mM, 0.01 mM, 0.4 mM and 0.09 mM, respectively. 4 In all experiments in the rabbit perfused kidney, endothelin-1 was readministered for a third time, 60 min following cessation of infusion of the above-mentioned antagonists. The response to the third infusion of endothelin-1 following cessation of infusion of BQ-123, BMS 182874 and SB 209670 was not signi®cantly dierent from that to the third infusion of endothelin in control conditions. However, the response to endothelin-1 was signi®cantly higher than control in tissues pre-infused with BQ-788 or BQ-928 (56+9 and 41.6+15%, respectively, n=8 each, P50.05). 5 Our results suggest that in a system where ET A receptor activation is responsible for vasoconstriction and ET B -receptor activation for vasodilatation, ET A receptor selective antagonists or mixed ET A /ET B receptor antagonists which possess high anity for ET A receptors do not induce hyperresponsiveness to endothelin-1. In contrast, ET B selective antagonists or mixed antagonists possessing a high anity for ET B receptors (such as BQ-928) interfere with the ET B -receptor-dependent physiological antagonism of endothelin-1-induced pressor responses in these same tissues.
Introduction
A recent study by Allcock et al. (1995) showed that in contrast to a selective ET A receptor antagonist, the mixed ET A /ET B receptor antagonist PD-145065 (Doherty et al., 1993) failed to prevent the reductions in blood¯ow in the kidney, splanchnic area, lung and skin induced by administration of endothelin-1 (ET-1) to the anaesthetized rat. From these results, the authors suggested that the predominant role of the ET B receptors within blood vessels of the rat is to limit the pressor eects of endothelin-1. It had been previously suggested that the systemic pressor eect of endothelin-1 in the rat is partly mediated by ET B receptors located on the smooth muscle of resistance vessels (McMurdo et al., 1993) . The observations of Allcock et al. (1995) con®rm our results obtained in a selective ET A -receptor dependent constrictive organ, the rabbit perfused kidney, in which the ET B receptor antagonist, BQ-788, sharply potentiates the vasoconstrictive eect of endothelin-1 (D'OrleÂ ans- .
In a more recent study, it was further shown that following interruption of the application of a mixture of ET A and ET B antagonists (BQ-123 plus BQ-788) (D'OrleÂ ans- Juste et al., 1995) , a renal hyperresponsiveness to endothelin-1 (i.e. enhanced vasoconstriction) was found in the rabbit perfused kidney. In that same study, we proposed that a reduction of the minimal eective plasma concentration of a mixture of ET A /ET B antagonists may lead to an exaggerated constriction to exogenous endothelin due to the non-reversible impairment of the ET B -dependent release of endothelium-derived relaxing factor (EDRF).
We were therefore interested, in the present study, to examine whether mixed ET A /ET B receptor antagonists would induce the same type of hyperresponsiveness as found in our previous experiments (D 'OrleÂ ans-Juste et al., 1995) . For that purpose, we have used a highly potent mixed ET A /ET B receptor antagonist, SB 209670 (Ohlstein et al., 1994) , together with BQ-123 and another selective ET A receptor antagonist, BMS 182874 (Stein et al., 1994) . In addition, a recent study by Fukami et al. (1995 Fukami et al. ( , 1996 disclosed two new mixed ET A /ET B receptor antagonists, namely BQ-928 and BQ-238. These antagonists have, as interesting characteristics, inverse anities for the two receptor populations. Namely, BQ-928 has a higher anity for ET B than ET A receptors, whereas BQ-238 possesses a higher anity for ET A than ET B receptors, similar to SB 209670.
Therefore, we initally characterized pharmacologically on ET A and ET B receptor containing vascular preparations, the pharmacodynamic characteristics of all these antagonists. Secondly, we compared their eciencies as blockers of en-dothelin-1-induced vasoconstrictions in the rabbit kidney, where vasoconstrictions are mediated soley by ET A receptors (TeÂ leÂ maque et al., 1993) . Thirdly, we evaluated the capacities of all of these antagonists to induce a signi®cant hyperresponsiveness of the kidney to endothelin-1 following interruption of their application.
Methods
All experiments were performed on tissues or organs removed from New-Zealand White rabbits (1.7 ± 2.5 kg) (ReÂ jean Brisebois, Fleurimont, Canada) of either sex, anaesthetized with ketamine/xylazine (40/10 mg kg 71 , i.m.) and then killed by spinal transection.
Rabbit carotid and pulmonary artery experiments
The vessels were removed and mechanically denuded of their endothelium. The rabbit carotid arteries were cut into 4 ± 6 mm wide rings, while rabbit pulmonary arteries were cut into spiral strips about 15 ± 20 mm long and 3 mm wide. The tissues were immediately suspended in 10 ml baths containing warmed (378C) and oxygenated (95% O 2 , 5% CO 2 ) Krebs solution with the addition of indomethacin (1 mM). The tissues were stretched for an equilibration period of 60 min with initial resting tensions of 2 g and 1 g for the carotid and pulmonary arteries, respectively, before initiation of experimental procedures. The incubation medium was changed every 15 min. During the 60 min equilibration period, the tension of tissues was constantly reapplied in all blood vessels. Tissues were linked to transducers (Grass Model FT03C) which were connected to a physiograph (Grass Model 7) to measure isometric contractile force. Before each experiment, the absence of endothelium was con®rmed by the inability of the tissue, precontracted with angiotensin II (10 nM), to relax in response to acetylcholine (1 mM). Concentration-response curves to agonists were constructed 15 min after application of the antagonist. The antagonist eects were evaluated in terms of displacement to the right of the agonist-induced concentration-response curves and pA 2 values were obtained by Schild plot analysis (Arunlakshana & Schild, 1959) . Control tissues, treated with vehicle, were always run in parallel. ED 50 values for the agonists were calculated from the linear regression performed on the doseresponse curve between 20% and 80% of the maximal eect for each agonist. EC 50 values were then transformed into pD 2 values (negative logarithm expression of the EC 50 ).
Rabbit perfused kidney experiments
In another series of experiments, a polyethylene catheter (Portex, tube size 6FG) was placed in the right renal artery from the freshly killed animals (as previously described) and the kidney was excised (within 1 min after death) while being continuously perfused (5 ml min 71 ) with heparinized (100 u ml 71 ) Krebs solution. The kidney was then rapidly placed in a heated chamber (378C) and perfused (5 ml min In further experiments, antagonists at concentrations which reduced the response to endothelin (10 nM) by at least 60% were infused from 15 min before the second administration of the agonist. Administration of antagonists was interrupted 5 min after the maximal response to endothelin-1 had been attained. Sixty minutes after treatment, endothelin-1 (10 nM) was infused a third time to measure reversibility.
To monitor oedema formation, the kidneys were weighed before being placed in the heated chamber and at the end of each experiment, which lasted for a maximum time period of 180 min. The mean weight of the kidneys was 8.4+0.2 g before and 11.1+0.3 g at the end of the experiments (n=51) (P50.01).
Drugs and solutions
Synthetic endothelin-1 was purchased from American Peptide (Sunnyvale, CA, U.S.A.). (Ihara et al., 1992) , (Ishikawa et al., 1994) , 
Statistics
Data used in the text and ®gures are expressed as mean+ s.e.mean of n observations. Statistical comparisons between groups were performed by paired or unpaired Student's t test. ANOVA followed by Dunnett multiple comparisons test was used for comparison of the response to one agonist varying with time. Values of P50.05 were considered statistically signi®cant.
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Results
Eect of selective and non-selective endothelin receptor antagonists in the rabbit carotid and pulmonary arteries
Endothelin-1 and IRL-1620 induced concentration-dependent contractions of the rabbit carotid artery (RbCA) and pulmonary artery (RbPA), respectively, with apparent anities (pD 2 ) of 9.36+0.14 (maximal tension of 2.2+0.12 g) and 8.82+0.10 (maximal tension of 1.15+0.10 g), respectively (n=21 for each preparation).
On the rabbit carotid artery, BQ-123, BQ-928, BQ-238, BMS 182874 and SB 209670 induced concentration-dependent rightward shifts of the concentration-response curves to endothelin-1, with Schild plot-extrapolated apparent anities (pA 2 ) of 6.41+0.24 (Calo et al., 1996), 7.22+0.18, 7.42+0.22, 6.20+0.21 and 9.22+0.21, respectively (Table 1) . In contrast, BQ-788 did not eect endothelin-1 induced contractions of the rabbit carotid artery at concentrations up to 1 mM (Calo et al., 1996) .
In another series of experiments, BQ-788, BQ-928, BQ-238 and SB 209670 induced rightward shifts of the concentrationresponse curve to IRL-1620 in the rabbit pulmonary artery, with Schild plot extrapolated apparent anities (pA 2 ) of 9.01+0.16 (Calo et al., 1996) , 8.43+0.04, 7.05+0.14 and 8.09+0.37, respectively (Table 1) . BQ-123 and BMS 182874 were without eect. In either preparation, all of the active antagonists competitively antagonized responses to the agonist with a Schild plot slope value not signi®cantly dierent from unity ( Figures 1 to 4) .
In a last series of control experiments, all these agonists were found to be inactive against contractions induced by angiotensin II (results not shown).
Eect of the selective or mixed ET A /ET B receptor antagonists on endothelin-1-induced constrictions of the rabbit perfused kidney
Before the various pharmacological agents were tested, the basal pefusion pressure of the kidney was 40.2+1.9 mmHg (n=51).
In an initial series of control experiments the vasocontrictor responses of the kidneys to three consecutive infusions of endothelin-1 (10 nM) were established to be 86+6, 100+10 and 117+5 mmHg (n=8) (Figure 5a ). The second and third administration of the peptide exhibited a 17.7+4.2% (non-signi®cant) and 39.1+7.8% (P50.05), increased response respectively, when compared to the eect of the ®rst infusion. In contrast, angiotensin II (1 mM, 5 min infusion) induced similar increases in renal perfusion pressure following three consecutive administrations (27.2+3.0; 23.0+3.3 and 27.5+5.2 mmHg, respectively, n=6).
All the antagonists, except BQ-788, reduced in a concentration-dependent manner the vasoconstrictor response of the rabbit perfused kidney to the second endothelin-1 infusion (10 nM) ( Table 2 ). The response to a second challenge with endothelin-1 was monitored in each kidney treated with a single concentration of one of the six antagonists.
The intrapolated IC 50 values for antagonists tested against the renal response to endothelin-1 are shown in Table 2 . The IC 50 value for BQ-123 against the response of the kidney to endothelin-1 has previously been established at 0.4 mM (TeÂ leÂ -maque et al., 1993). The rank order of potency of the antagonists was: SB 209670 4BQ-238 4BQ-928= BQ-123 4 BMS 182874 444 BQ-788.
Reversibility of the antagonistic eects of selective or mixed ET A /ET B receptor antagonists in the rabbit perfused kidney
The response of the rabbit perfused kidney to a third infusion of endothelin-1 was not signi®cantly dierent in BQ-123, BQ-238 and SB 209670 treated organs compared to untreated ( 1 9 9 6 ) . controls. Furthermore, the response to BMS 182874 was found to be less (722.7+8.3%) (P50.05, n=7) than in untreated controls. In contrast, the response to endothelin-1 was found to be higher than in controls in reversibility experiments of kidneys treated with either BQ-788 (56.0+9.0%) (P50.05, n=8) or BQ-928 (41.6+15.0%) (P50.05, n=6).
In another series of experiments, the responses of rabbit perfused kidney to angiotensin-II (1 mM) were shown to be unaected by any of the antagonists used in the present study (results not shown).
Discussion
One of the main purposes of the present study was ®rstly to establish the pharmacological characteristics of the recently developed mixed ET A /ET B antagonists, BQ-238 and BQ-928, in comparison to other well-established antagonists, such as SB 209670 (Ohlstein et al., 1994) . It was found in our study that BQ-238, but not BQ-928, possesses a higher anity for ET A than for ET B receptors. These results have been con®rmed in two highly selective preparations, the rabbit carotid artery and pulmonary artery (with IRL-1620 as a selective ET B agonist). The higher anity of BQ-928 or BQ-238 for the ET A or ET B receptors con®rmed the observations of Fukami et al. (1996) ; they showed, using the natural agonist endothelin-1, the same receptor selectivity for these particular antagonists in porcine aortic smooth muscle or cerebellum membrane selective for the ET A or ET B receptors, respectively. With these two preparations, we have also con®rmed the anity and selectivity of BMS 182874 for ET A receptors, as initially demonstrated by Stein et al. (1994) .
In a recent study, we have shown that a mixture of BQ-123 (1 mM) and BQ-788 (10 nM) although eciently blocking the vasoconstriction to endothelin-1 in the rabbit perfused kidney, induced a marked hyperresponsiveness to a third infusion of endothelin-1 given 1 h after cessation of the antagonist treatment (D'OrleÂ ans-Juste et al., 1995). In the present study, the mixed ET A /ET B receptor antagonist BQ-928 also induced the same hyperresponsiveness to endothelin-1. Interestingly, this type of hyperreactivity was not seen following interruption of the infusion of SB 209670 or BQ-238. We would suggest that this lack of hyperresponsiveness is due to the fact that both compounds have much higher anities for ET A than ET B receptors. The highly tachyphylactic nature of the endothelial ET B receptor-mediated response (Le Monnier De Gouville et al., 1990) may explain the signi®cant increase in responsiveness of the kidney to a third control infusion of endothelin-1, a phenomenon not seen with angiotensin II. Nonetheless, treatment of the kidney with a mixture of BQ-123 and BQ-788 (D'OrleÂ ans-Juste et al., 1995) or with BQ-928 still triggered a signi®cant increase in the response to a third infusion of endothelin-1 when compared to the third control infusion.
On the other hand, it has been established that the ET B receptor found on the endothelium is pharmacologically and biochemically indistinguishable from the ET B receptors found on the smooth muscle (Clozel & Gray, 1995) . Moreover, Warner (1993) demonstrated the presence of ET B receptor subtypes (ET B1 and ET B2 ) in rat arterial mesenteric vasculature and stomach strips. Nonetheless, results obtained from the ET B -receptor selective, and contractile, preparation of the rabbit pulmonary artery (with IRL-1620 as an agonist) may be extrapolated to the function of the same receptor type on the endothelium of the kidney, as previously suggested (D'OrleÂ ans-Juste et al., 1994). As we have previously shown in the rabbit that BQ-788 potentiates the pressor and renal constrictor eects of endothelin-1 (D'OrleÂ ans- , the results of the present study support the preferential use of selective ET A antagonists in the human renal circulation in pathological situations where raised levels of endogenous endothelin-1 may be important. This hypothesis is based on the assumption that small diameter vessels will respond to endothelin-1, principally via ET A receptors, as already demonstrated in larger human renal vessels (Maguire et al., 1994) .
The above-mentioned concept is further supported by the recent observation of Allcock et al. (1995) that in the anaesthetized rat mixed ET A /ET B receptor antagonists such as PD-145065 are incapable, unlike BQ-123, of reversing the reductions in blood¯ow in dierent tissues induced by endothelin-1, due to their ability to block the ET B receptor-dependent release of endothelium-derived relaxing factor. Interestingly, the mixed ET A /ET B receptor antagonist, BQ-928, similar to PD-145065, possesses a higher anity for ET B than for ET A receptors.
Although BQ-238 and BQ-928 are almost equipotent as antagonists of contractions of the RbCA induced by endothelin-1, the latter is much more potent in blocking the constriction induced by IRL-1620 in the RbPA. This dierence in anity for both ET A and ET B receptor types may explain the lower potency of BQ-928 compared to BQ-238 as a blocker of the renal constriction to endothelin-1 and the hyperresponsiveness that follows the interruption of its infusion into the rabbit kidney.
The non-peptidic antagonist, BMS 182874, which is selective for ET A receptors, was signi®cantly less reversible as a blocker of ET-1-induced renal constriction than were BQ-123 or the mixed ET A /ET B receptor antagonists. Indeed, although SB 209670 and BMS 182874 are metabolically stable compounds, only the latter ET A receptor selective blocker retained a signi®cant antagonist eect for more than 60 min following its interruption.
Bosentan, which possesses a higher anity for ET A than for ET B receptors, has been shown to improve cardiopulmonary vascular performance in a porcine endotoxic model (Weitzberg et al., 1996) . In contrast, Ruetten et al. (1996) have recently demonstrated that endothelin-1 may be important in the maintenance of vascular tone in conditions of septic shock induced by LPS. In this latter study, the authors demonstrated that SB 209670 exacerbates the damage induced by septic shock in the anaesthetized rat. It is noteworthy that both ET A and ET B receptors mediate increases in vascular resistance induced by administration of exogenous endothelin-1 in anaesthetized rats (McMurdo et al., 1993) . However, the pathological states seen in various vasculatures during septic shock cannot be entirely explained by reductions in the blood supply to these organs, caused by a drop in mean arterial pressure. A particular example of this is the marked increase in renal resistance encountered in endotoxin-treated rats (Mulder et al., 1993) . Antagonists such as SB 209670, which interfere with both ET A and ET B receptor-mediated vasoconstriction in the rat as well as ET B -receptor dependent release of EDRF (Ohlstein et al., 1994) , will interfere not only with the increase in vascular resistance induced by endothelin, but will also affect the ET B -receptor-dependent increase in blood¯ow, which is L-NAME-sensitive, at least in the renal circulation of the rabbit (D'OrleÂ ans- . On the other hand, treatment with bosentan in the endotoxic pig model (Weitzberg et al., 1996) was signi®cantly less lethal than treatment with SB 209670 in the rat model (over 60% of the animals died; Ruetten et al., 1996) . The lesser toxicity of bosentan, when compared to SB 209670, may be due to the predominant role of ET A receptors as mediators of the pressor eects of ET-1 in the pig (Cirino et al., 1992) as opposed to the rat where both ET A and ET B receptors are involved in the endothelin-1-induced increase of mean arterial pressure (McMurdo et al., 1993) and reduction of renal blood¯ow (Wellings et al., 1993) . Interestingly, Clozel and Breu (1996) have recently demonstrated a predominant role of endothelial`vasorelaxant' ET B receptors in deoxycorticosterone acetate (DOCA) and spontaneously hypertensive rats but not in normal rats, with the orally-available ET B receptor antagonist Ro 46-8443.
A recent study by Haynes et al. (1996) has shown that the mixed ET A /ET B receptor antagonist TAK-044 increases blood ow by 22% in the forearm arteries of healty subjects whereas BQ-123 increases it by 75% (Haynes & Webb, 1994) . The weaker eect of TAK-044 in increasing forearm blood¯ow may well be due to its ability to interfere with ET B receptordependent vasodilation induced by endogeneous endothelin-1.
Overall, our results show that mixed ET A /ET B receptor antagonists which possess a higher anity for ET B than for ET A receptors induce hyperresponsiveness following interruption of their application to organs in which ET A receptors largely mediate endothelin-1 resistance vasoconstrictions, such as the rabbit kidney (TeÂ leÂ maque et al., 1993) . In order to avoid these deleterious eects, which may be dependent on the in vivo pharmacokinetic characteristics of these compounds, we would advocate the use of either highly selective ET A receptor antagonists or mixed ET A /ET B receptor antagonists which possess much higher anities for ET A than ET B receptors. 
